GENEVA (AP) — The U.N.-backed program to ship COVID-19 vaccines worldwide has announced supply delays for up to 90 million doses from an Indian manufacturer, in a major setback for the ambitious rollout aimed to help low- and middle-income countries fight the pandemic.
Gavi, the Vaccine Alliance, said Thursday that the delays come as India is facing a surge of coronavirus infections that will increase domestic demands on the Serum Institute of India, a pivotal vaccine maker behind the COVAX program.
“Delays in securing supplies of SII-produced COVID-19 vaccine doses are due to the increased demand for COVID-19 vaccines in India,” Gavi said.
The move will affect up to 40 million doses of the Oxford University-AstraZeneca vaccines being manufactured by the Serum Institute that were to be delivered for COVAX this month, as well as 50 million expected next month. Gavi said it has notified recipient countries.
The institute has been contracted to supply vaccines to 64 countries, and Gavi said the U.N.-backed program has “notified all affected economies of potential delays.”
Gavi said the Serum institute has pledged that “alongside supplying India, it will prioritize the COVAX multilateral solution for equitable distribution.”
Gavi, which runs COVAX jointly with the World Health Organization and the Coalition for Epidemic Preparedness Innovations, has already distributed 31 million doses of the AstraZeneca vaccine — 28 million from the Serum Institute and another 3 million from a South Korean contractor also producing the vaccine.
The program had been aiming to deliver some 237 million AstraZeneca vaccines through the end of May. A Gavi spokesman said the delays were not expected to affect the goal of shipping some 2 billion doses worldwide through COVAX by the end of the year.
COVAX has so far shipped vaccines to some 50 countries and territories.